Targeted radionuclide therapy and molecular imaging have reshaped precision medicine, with Radionuclide-Drug Conjugates (RDCs) at the forefront. RDCs combine tumor‑selective vectors (small molecules, peptides, antibodies) with diagnostic or therapeutic radionuclides, enabling simultaneous disease detection and treatment. As a premier research service provider, Alfa Cytology offers a comprehensive, end-to-end RDC development platform designed to accelerate your therapeutic and diagnostic pipelines from initial concept to clinical application. By integrating cutting-edge radiolabeling, radioligand binding assays, and rigorous preclinical evaluation, we deliver tailor-made, turnkey solutions that address the unique chemical, biological, and radiological complexities of your targeted radiopharmaceuticals.
Radionuclide-Drug Conjugates (RDCs) consist of four modular components: a targeting ligand (e.g., peptide, antibody, small molecule), a linker, a radionuclide‑chelating moiety (or direct labeling chemistry), and a radioactive isotope. The targeting domain directs the construct to a disease‑associated antigen or receptor, while the radionuclide provides either an imaging signal (positron or gamma emitter) or cytotoxic radiation (alpha, beta, or Auger electron emitter). This sophisticated architecture allows for unprecedented precision, delivery of localized radiation payloads, and real-time pharmacokinetic tracking in vivo.
Fig.1 RDC drug architecture and pharmacological mechanism. (Xijing, L., and Cheng, B., 2025)
The integrated RDC platform supports diverse medical and clinical applications, bridging the gap between discovery and targeted nuclear medicine to address unmet oncological and diagnostic needs.
Targeted Oncological Therapeutics
Deliver highly localized, high-energy radiation (via alpha or beta emitters) directly to cancer cells to induce DNA double-strand breaks, effectively treating primary tumors and micro-metastases while sparing healthy surrounding tissues.
Precision Molecular Imaging
Utilize positron emission tomography (PET) or single-photon emission computed tomography (SPECT) to non-invasively visualize tumor receptor expression, map biodistribution, and monitor treatment response in real time.
Companion Diagnostics (Theranostics)
Screen and stratify patients who are most likely to respond to specific targeted radioligand therapies, thereby optimizing clinical trial designs, minimizing off-target risks, and establishing personalized treatment regimens.
Dose Optimization and Dosimetry Studies
Quantify exact radiation dosimetry profiles in vivo through advanced pharmacokinetic modeling to maximize therapeutic efficacy, determine optimal dosing intervals, and establish strict safety thresholds for critical organs at risk (OARs).
Leveraging deep expertise in radiochemistry, parallel‑track ligand optimization, and regulatory‑aligned preclinical safety models, Alfa Cytology delivers a complete suite of integrated RDC development services. Our platform bridges the gap between novel conjugate design and IND‑enabling studies, offering clients a single‑source solution that accelerates timelines, reduces technical risks, and ensures absolute data consistency across discovery and development phases.
Alfa Cytology's dedicated radiolabeling suite is fully equipped to handle a diverse spectrum of isotopes, ensuring stable and efficient conjugation across various modalities. We offer precise labeling optimization, rigorous quality control, and comprehensive analytical validation to deliver highly pure radiopharmaceuticals tailored to your specific research requirements, spanning alpha-emitters, beta-emitters, and diagnostic isotopes.
| Isotopes | Half-life | Imaging Type | Description |
|---|---|---|---|
| 14C | 5730Y | / | Long‑lived beta emitter used in drug development for ADME studies and breath tests. |
| 3H | 12.3Y | / | High-specific-activity tracer for preclinical pharmacokinetic and metabolism research. |
| 18F | 110M | PET | PET imaging for tumors, myocardium, central nervous system, and bone. |
| 89Zr | 78.4H | PET | PET tracer for immuno-PET with antibodies and other large biomolecules. |
| 99mTc | 6H | SPECT | SPECT imaging for heart, brain, kidney, lung, and other organs. |
| 64Cu | 12.7H | PET | PET imaging and emerging targeted radiotherapy. |
| 123I | 13.22H | SPECT | Diagnostic SPECT isotope for thyroid and neuroendocrine tumor imaging. |
| 125I | 60D | / | Used for in vitro radioassays, research, and as a low‑energy brachytherapy source. |
| 131I | 8D | SPECT | Treatment of hyperthyroidism and thyroid cancer (also diagnostic SPECT imaging). |
| 177Lu | 6.7D | SPECT | SPECT imaging and targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. |
| 225Ac | 10D | / | Potent alpha emitter for targeted alpha therapy (TAT) of advanced cancers. |
| 111In | 2.8D | SPECT | Used for SPECT imaging with radiolabeled antibodies, peptides, or other targeted vectors (radioimmunoimaging). |
| 211At | 7.2H | / | Investigational alpha emitter for targeted alpha therapy. |
| 13C | Stable | / | Stable isotope for metabolic flux and pharmacokinetic studies via MS or NMR. |
| 89Sr | 50D | / | Beta emitter for pain palliation of bone metastases. |
| 90Y | 64H | / | Radioembolization for liver cancer; radioimmunotherapy for lymphoma; radiation synovectomy for rheumatoid arthritis and hemophilic synovitis. |
| 47Sc | 3.3D | SPECT | Emerging theranostic isotope: SPECT imaging and beta therapy. |
| 68Ga | 68M | PET | Tumor PET imaging, notably using 68Ga-labeled SSTR imaging agents. |
| 188Re | 16.9H | SPECT | Management of bone metastasis pain and other cancer therapies. |
| 153Sm | 46.5H | SPECT | Medium‑energy beta emitter for palliative treatment of osteoblastic bone metastases. |
| 161Tb | 6.9D | SPECT | Emerging theranostic isotope: SPECT imaging and beta/Auger therapy; properties similar to ¹⁷⁷Lu. |
| 32P | 14.3D | / | Beta emitter used in myeloproliferative disorders (e.g., polycythemia vera) and as a research tracer. |
| 103Pd | 17D | / | Low-energy photon emitter used in permanent seed brachytherapy (e.g., prostate cancer). |
Offering versatile, high-precision bioconjugation technologies systematically tailored to the molecular weight, structural complexity, and pharmacokinetic requirements of diverse targeting vectors to maximize in vivo stability and therapeutic index.
Providing modular, phase-specific services that support your project through every milestone of the early-stage pipeline, ensuring a seamless, highly rigorous, and data-driven transition from initial design to investigator-initiated clinical research.
Formulate customized structural architectures pairing the most suitable targeting vectors with specific therapeutic or diagnostic radionuclides based on the target biology.
Discover, screen, and engineer high-affinity targeting domains, including peptides and single-chain fragments, optimized for rapid in vivo distribution and clear target contrast.
Linker Design and Synthesis Service
Construct innovative, customizable linkers, including cleavable, non-cleavable, hydrophilic, or PEGylated variants, tailored precisely to modulate the desired blood clearance profiles and stability.
Chelator Screening and Synthesis Service
Evaluate an extensive library of macrocyclic and acyclic chelators to select the optimal coordination match for specific radiometals based on thermodynamic stability.
Execute precise manual and automated bioconjugation processes under strictly controlled, optimized reaction parameters to maintain ligand immunoreactivity and structural integrity.
Implement optimized radiolabeling methods achieving high radiochemical yield and specific activity while minimizing unreacted free isotopes through advanced, high-recovery purification workflows.
Perform strict quality control analysis encompassing radiochemical purity, specific activity, long-term in vitro serum stability, and detailed target binding kinetics validation.
Support investigator-initiated trials by providing regulatory-compliant dose formulation protocols, complete radiolabeling batch records, and robust preclinical data packages.
Categorizing functional assays and development streams to address the distinct mechanism of action, validation requirements, and research intent of your candidate molecules, matching the precise therapeutic or diagnostic goals of your pipeline.
Optimize candidates for maximal localized cytocidal efficacy, focusing on delivering targeted high-linear energy transfer alpha or beta radiation to tumor sites to induce lethal DNA double-strand breaks.
Design high-contrast imaging probes engineered for highly sensitive tumor detection, precise staging, real-time target expression quantification, and accurate longitudinal treatment monitoring via nuclear medicine modalities.
Support Boron Neutron Capture Therapy (BNCT) pipelines by designing and evaluating boron-rich carrier agents optimized for high tumor-selective accumulation and prolonged intracellular retention prior to neutron irradiation.
Develop versatile, specialized radiolabeled research probes to serve as essential tools for early-stage target validation, mapping exact in vivo pharmacokinetics, and conducting companion diagnostic screening.
From the first radiolabeling trial to a preclinical data package ready for regulatory submission, Alfa Cytology's integrated R&D solutions for RDC drugs provide the scientific rigor, operational reliability, and strategic guidance needed to advance novel radiopharmaceuticals efficiently. Contact our expert team to discuss how we can customize our end-to-end platform to accelerate your next breakthrough in radiopharmaceutical innovation.
Reference
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.